Harris A Eyre
Harris A Eyre, M.D., Ph.D.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Robert Lundin
Robert Lundin, B.Sc., M.B.B.Ch.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Veronica Podence Falcão
Veronica Podence Falcão, M.D.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Michael Berk
Michael Berk, M.D., Ph.D.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Tadeusz Hawrot
Tadeusz Hawrot, M.Sc.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Marion Leboyer
Marion Leboyer, M.D., Ph.D.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Frederic Destrebecq
Frederic Destrebecq, M.Sc.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Zoltan Sarnyai
Zoltan Sarnyai, M.D., Ph.D.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Charles Reynolds III
Charles Reynolds III, M.D.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Helen Lavretsky
Helen Lavretsky, M.D., M.S.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Kavitha Kolappa
Kavitha Kolappa, M.D., M.P.H.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1,
Jeffrey Cummings
Jeffrey Cummings, M.D., Sc.D.
1Brain Capital Alliance (HAE, VPF, MB, FD, JC), San Francisco, CA; Neuroscience-Inspired Policy Initiative (NIPI), New Approaches to Economic Challenges, Office of the Chief Economist, Organisation for Economic Co-Operation and Development (HAE, VPF, MB, TH, FD, JC), Paris, France; Center for Health and Biosciences, The Baker Institute for Public Policy, Rice University (HAE), Houston, TX; Meadows Mental Health Policy Institute (HAE), Dallas, TX; Euro-Mediterranean Economists Association (HAE), Barcelona, Spain; Institute for Mental and Physical Health and Clinical Translation (IMPACT), Deakin University and Barwon Health (HAE, RL, VPF, MB), Geelong, Victoria, Australia; Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine (HAE, MB), Houston, TX; Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center (HAE, MB), Houston, TX; Department of Psychiatry, University of Melbourne (MB), Parkville, Victoria, Australia; The Florey Institute for Neuroscience and Mental Health, University of Melbourne (MB), Parkville, Victoria, Australia; ORYGEN Youth Health, University of Melbourne (MB), Parkville, Victoria, Australia; European Federation for Neurological Associations (TH), Brussels, Belgium; Psychedelic Access and Research European Alliance (PAREA) (TH), Brussels, Belgium; IMRB Translational Neuropsychiatry Lab (ML), Université Paris Est Creteil, Creteil, France; Department of Psychiatry and Addictology (ML), Hôpitaux Universitaires Henri Mondor, Créteil, France; Fondation FondaMental (ML), Creteil, France; European Brain Council (FD), Brussels, Belgium; Laboratory of Psychiatric Neuroscience, Australian Institute of Tropical Health and Medicine, James Cook University (ZS), Townsville, Queensland, Australia; Department of Psychiatry, University of Pittsburgh (CR), Pittsburgh, PA; Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles (UCLA) (HL), Los Angeles, CA; The Chester M. Pierce MD Division of Global Psychiatry, Department of Psychiatry, Massachusetts General Hospital (KK), Boston, MA; and the Chambers-Grundy Center for Transformative Neuroscience, University of Nevada (JC), Las Vegas, NV
1